This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.

This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.

Provided is an herbal composition including an extract from a combination of herbs including at least five of Forsythia suspensa, Scutellaria baicalensis, Bupleurum chinese, Magnolia officinalis, Agastache rugosa, Astragalus membranaceus, Atractylodes macrocephala, and seeds of Ligustrum lucidum. Also provided is a method for preparing the herbal composition and a method for preventing or treating a viral infection by administering an effective amount of the herbal composition to a subject in need thereof.

Provided is an herbal composition including an extract from a combination of herbs including at least five of Forsythia suspensa, Scutellaria baicalensis, Bupleurum chinese, Magnolia officinalis, Agastache rugosa, Astragalus membranaceus, Atractylodes macrocephala, and seeds of Ligustrum lucidum. Also provided is a method for preparing the herbal composition and a method for preventing or treating a viral infection by administering an effective amount of the herbal composition to a subject in need thereof.

Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Myristica extract, at least one Astragalus extract, and at least one Schizandra extract. Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Myristica extract enriched for one or more lignans, including phenylpropanoids, dimers and polymers, at least one Astragalus extract enriched for one or more polysaccharides and triterpenoids, and at least one Schizandra extract enriched for one or more lignans and organic acids. Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Myristica extract, at least one Astragalus extract, and at least one Poria extract.

Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Myristica extract, at least one Astragalus extract, and at least one Schizandra extract. Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Myristica extract enriched for one or more lignans, including phenylpropanoids, dimers and polymers, at least one Astragalus extract enriched for one or more polysaccharides and triterpenoids, and at least one Schizandra extract enriched for one or more lignans and organic acids. Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Myristica extract, at least one Astragalus extract, and at least one Poria extract.

Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Myristica extract, at least one Astragalus extract, and at least one Schizandra extract. Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Myristica extract enriched for one or more lignans, including phenylpropanoids, dimers and polymers, at least one Astragalus extract enriched for one or more polysaccharides and triterpenoids, and at least one Schizandra extract enriched for one or more lignans and organic acids. Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Myristica extract, at least one Astragalus extract, and at least one Poria extract.

The present invention relates to a drug for treating leukopenia, its preparation method and use thereof. The drug of the invention is prepared from 200-30 parts by weight of Folium Epimedii, 100-160 parts by weight of Fructus Psoraleae, 60-120 parts by weight of Radix Aconiti Lateralis Preparata (Processed), 200-300 parts by weight of Fructus Lycii, 200-300 parts by weight of Radix Astragali, 200-300 parts by weight of Caulis Spatholobi, 200-300 parts by weight of Radix Rubiae, 100-160 parts by weight of Radix Angelicae Sinensis, 200-300 parts by weight of Rhizoma Phragmitis, 100-160 parts by weight of Radix Ophiopogonis and 100-160 parts by weight of Radix et Rhizoma Glycyrrhizae. The drug of the invention comprises chemical substances with weight ratios as follows: Leucine:guanosine:psoralenoside:isopsoralenoside:calycosin-7-glucoside:liquiritin:icariin A:1,3-dihydroxyl-2-hydroxymethylanthraquinone:epimedin A:epimedin B:epimedin C:icariin:1,3,6-trihydroxy-2-methylanthraquinone:glycyrrhizic acid=(0.13-0.27):(0.04-0.11):(0.11-0.34):(0.09-0.34):(0.05-0.11):(0.16-0.26):(0.09-0.12):(0.17-0.35):(0.11-0.16):(0.17-0.26):(0.49-0.59):1.00:(0.16-0.24):(0.08-0.14).

The present invention relates to a drug for treating leukopenia, its preparation method and use thereof. The drug of the invention is prepared from 200-30 parts by weight of Folium Epimedii, 100-160 parts by weight of Fructus Psoraleae, 60-120 parts by weight of Radix Aconiti Lateralis Preparata (Processed), 200-300 parts by weight of Fructus Lycii, 200-300 parts by weight of Radix Astragali, 200-300 parts by weight of Caulis Spatholobi, 200-300 parts by weight of Radix Rubiae, 100-160 parts by weight of Radix Angelicae Sinensis, 200-300 parts by weight of Rhizoma Phragmitis, 100-160 parts by weight of Radix Ophiopogonis and 100-160 parts by weight of Radix et Rhizoma Glycyrrhizae. The drug of the invention comprises chemical substances with weight ratios as follows: Leucine:guanosine:psoralenoside:isopsoralenoside:calycosin-7-glucoside:liquiritin:icariin A:1,3-dihydroxyl-2-hydroxymethylanthraquinone:epimedin A:epimedin B:epimedin C:icariin:1,3,6-trihydroxy-2-methylanthraquinone:glycyrrhizic acid=(0.13-0.27):(0.04-0.11):(0.11-0.34):(0.09-0.34):(0.05-0.11):(0.16-0.26):(0.09-0.12):(0.17-0.35):(0.11-0.16):(0.17-0.26):(0.49-0.59):1.00:(0.16-0.24):(0.08-0.14).

Exemplary embodiments relate to a manufacturing method of herbal medicine processed food. The method comprises (a) drying raw materials of Leonurus japonicus Houtt, Dioscorea bulbifera, Solanum nigrum L, Scutellaria baicalensis, Akebiae Caulis, corn silk, Astragalus membranaceus, Pueraria lobata Ohwi, and Lithospermum erythrorhizon by means of vacuum drying, wherein the drying temperature is 20 to 80° C., (b) grinding each of the vacuum-dried raw material of the step (a) to produce powder, (c) shaping mixture of powder of the step (b) into a round shape.